Experimental peptide

BPC-157

Massive online interest; very limited mature human clinical evidence.

Evidence Maturity · M2 - Preliminary human Not FDA-approved
Evidence reviewed: September 19, 2026Source-labeled

Signal summary

BPC-157 is one of the best examples of the gap between biological plausibility, preclinical enthusiasm, and mature human evidence.

Signal interpretation: The correct conclusion is not 'BPC-157 definitely does nothing.' It is that the claims currently outrun the human evidence. RecompSignal will label that gap instead of filling it with anecdotes.

Study details

Doses studied — not a dosing recommendation. Regimens belong to the named study, formulation and population.

Small intravenous safety pilot

Population
Two adults who had previously received intravenous BPC-157.
Doses and administration studied
The pilot reported 10 mg intravenously on day 1 and 20 mg on day 2. These are observations from a tiny study, not an established clinical regimen.
Duration
Short observation across three days
Reported finding / status
No adverse effects were reported in the two participants during the observation period.
Interpretation and limitations
No control group, two participants and brief follow-up cannot establish general safety, healing efficacy or recomposition benefit. No established clinical dosing regimen.

Source tier C · Read the original study or record

Outcome Evidence Strength

Weight change0/5
Fat-mass change0/5
Lean-mass change0/5
Strength / function benefit0/5

No adequate human weight, fat, lean-mass or functional efficacy evidence is established by this safety pilot.

Editorial evidence ratings for the cited outcomes, not effect size or treatment recommendations. A lean-mass score may describe loss. 0 means not established in the reviewed evidence, not proof of no effect. Read the rubric.

What is actually established?

  • A 2026 review described decades of preclinical research but no approved formulation and no completed Phase II clinical trial.
  • Human evidence remains sparse relative to the breadth of claims made online.
  • The peptide remains investigational.

What is not established?

  • Broad efficacy for tendon, ligament, gastrointestinal, neurologic, or whole-body 'healing' claims has not been established in large controlled human trials.
  • A small number of human observations cannot characterize population-level safety.
  • There is no established body-recomposition role.

Evidence sources

A = regulatory/official • B = peer-reviewed randomized/meta-analysis • C = peer-reviewed review/observational • D = registered trial • E = sponsor-reported • F = preclinical

Source tier C: 2026 translational review
BPC-157 as an Investigational Peptide Therapeutic
Educational use only. This page summarizes research evidence and regulatory status. Study doses describe research, not prescribing instructions. This page does not provide personalized dosing, self-use protocols, sourcing, or a recommendation to use this therapy.